Wedbush Has Optimistic Outlook of Gossamer Bio Q3 Earnings

Key Points

• Wedbush raised its Q3 2025 EPS estimate for Gossamer Bio to ($0.18) from ($0.19), maintaining an "Outperform" rating with a price target of $5.00.
• The current consensus rating for Gossamer Bio is a Moderate Buy, with an average price target of $8.50 following various analysts' assessments.
• Gossamer Bio reported a beat on EPS expectations in its latest earnings release, with results of ($0.17), surpassing the consensus estimate of ($0.18).

Gossamer Bio, Inc. (NASDAQ:GOSS - Free Report) - Research analysts at Wedbush boosted their Q3 2025 EPS estimates for Gossamer Bio in a report released on Wednesday, August 6th. Wedbush analyst L. Chico now expects that the company will earn ($0.18) per share for the quarter, up from their prior forecast of ($0.19). Wedbush has a "Outperform" rating and a $5.00 price target on the stock. The consensus estimate for Gossamer Bio's current full-year earnings is ($0.28) per share. Wedbush also issued estimates for Gossamer Bio's FY2025 earnings at ($0.70) EPS and FY2029 earnings at ($0.37) EPS.

Other equities analysts have also recently issued research reports about the company. Scotiabank initiated coverage on Gossamer Bio in a report on Monday, July 14th. They issued a "sector outperform" rating and a $11.00 target price for the company. Wall Street Zen downgraded Gossamer Bio from a "hold" rating to a "sell" rating in a research report on Saturday. Finally, The Goldman Sachs Group boosted their price objective on shares of Gossamer Bio from $7.00 to $8.00 and gave the company a "buy" rating in a research report on Friday, May 16th. One analyst has rated the stock with a sell rating and four have assigned a buy rating to the company. According to data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and an average price target of $8.50.

Gossamer Bio Trading Up 1.1%

Shares of NASDAQ GOSS opened at $1.76 on Monday. Gossamer Bio has a 1-year low of $0.66 and a 1-year high of $2.23. The company has a debt-to-equity ratio of 6.70, a current ratio of 4.40 and a quick ratio of 4.40. The business's 50 day moving average is $1.51 and its two-hundred day moving average is $1.25. The stock has a market capitalization of $400.19 million, a P/E ratio of -2.84 and a beta of 1.96.

Gossamer Bio (NASDAQ:GOSS - Get Free Report) last announced its earnings results on Tuesday, August 5th. The company reported ($0.17) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.18) by $0.01. Gossamer Bio had a negative net margin of 344.81% and a negative return on equity of 1,774.72%. The firm had revenue of $11.49 million for the quarter, compared to analysts' expectations of $4.12 million.

Institutional Investors Weigh In On Gossamer Bio

Several hedge funds and other institutional investors have recently modified their holdings of GOSS. Octagon Capital Advisors LP boosted its holdings in Gossamer Bio by 99.7% during the 4th quarter. Octagon Capital Advisors LP now owns 18,350,000 shares of the company's stock valued at $16,599,000 after acquiring an additional 9,162,117 shares during the period. Alyeska Investment Group L.P. increased its stake in Gossamer Bio by 52.7% in the fourth quarter. Alyeska Investment Group L.P. now owns 8,808,514 shares of the company's stock worth $7,968,000 after purchasing an additional 3,041,058 shares during the period. Geode Capital Management LLC lifted its position in shares of Gossamer Bio by 100.4% during the second quarter. Geode Capital Management LLC now owns 4,555,080 shares of the company's stock worth $5,604,000 after purchasing an additional 2,282,632 shares during the last quarter. Acadian Asset Management LLC boosted its stake in shares of Gossamer Bio by 24.6% during the first quarter. Acadian Asset Management LLC now owns 6,358,113 shares of the company's stock valued at $6,991,000 after purchasing an additional 1,253,353 shares during the period. Finally, Goldman Sachs Group Inc. boosted its stake in shares of Gossamer Bio by 720.2% during the first quarter. Goldman Sachs Group Inc. now owns 939,603 shares of the company's stock valued at $1,034,000 after purchasing an additional 825,047 shares during the period. 81.23% of the stock is currently owned by hedge funds and other institutional investors.

Gossamer Bio Company Profile

Gossamer Bio, Inc, a clinical-stage biopharmaceutical company, focuses on developing and commercializing seralutinib for the treatment of pulmonary arterial hypertension (PAH) in the United States. The company is developing GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colony-stimulatin factor 1 receptor and c-KIT inhibitor, which is in Phase 3 clinical trial for the treatment of PAH.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.